Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Seok Rye Choi"'
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-17 (2024)
Abstract Background Recent advancements in positron emission tomograph (PET) using prostate specific membrane antigen (PSMA)-targeted radiopharmaceuticals have changed the standard of care for prostate cancer patients by providing more accurate infor
Externí odkaz:
https://doaj.org/article/c68203cee7834f80a54764d3e4f6a5e3
Autor:
Zhihao Zha, Seok Rye Choi, Linlin Li, Ruiyue Zhao, Karl Ploessl, Xinyue Yao, David Alexoff, Lin Zhu, Hank F. Kung
Publikováno v:
Journal of Medicinal Chemistry. 65:13001-13012
Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis and radionuclide therapy of prostate cancer. This study reports conversion of a previously reported
Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [18F]AlF-P16-093
Publikováno v:
Bioconjugate Chemistry. 32:1017-1026
Prostate-specific membrane antigen (PSMA)-targeted radioligands have played an increasing role in the diagnosis of prostate cancer. [68Ga]Ga-P16-093 is a PSMA-targeting agent for positron emission tomography imaging, currently under a Phase 2 clinica
Publikováno v:
Nuclear Medicine and Biology. 92:97-106
Introduction Since the approval of three 18F labeled β-amyloid-targeting PET imaging agents, Amyvid (florbetapir f18, AV-45), Neuraceq (florbetaben f18, AV-1) and Vizamyl (flutemetamol f18, F-PIB), they have increasingly been employed to assist diff
Publikováno v:
Molecular Pharmaceutics. 17:4589-4602
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells and therefore is an attractive target for prostate cancer diagnosis and radionuclide therapy. Recently, published results from clinical studies using a new PSMA-targe
Autor:
Kyle J. Labban, Karl Ploessl, Janet S. Reddin, Robert K. Doot, Erin K. Schubert, Hank F. Kung, Seok Rye Choi, David Alexoff, Hsiaoju Lee, Lin Zhu, Hwan Lee, Daniel A. Pryma, Zhihao Zha, Margaret E. Daube-Witherspoon, Zehui Wu, Joel S. Karp, Anthony J. Young
Publikováno v:
Nucl Med Biol
INTRODUCTION: [(68)Ga]Ga-P15-041 ([(68)Ga]Ga-HBED-CC-BP) is a novel bone-seeking PET radiotracer that can be generator-produced. We undertook a Phase 0/I clinical trial to assess its potential for imaging bone metastases in prostate cancer including
Autor:
Seok Rye Choi, David Alexoff, Hank F. Kung, Zehui Wu, Megan Smith, Karl Ploessl, Lin Zhu, Zhihao Zha
Publikováno v:
Molecular Pharmaceutics. 17:1674-1684
Positron emission tomography (PET) imaging using 68Ga-labeled bisphosphonates to target bone metastasis could be a valuable tool in cancer diagnosis and monitoring therapeutic treatment. A 68Ga labeled ligand, N,N'-bis[2-hydroxy-5-(carboxyethyl)benzy
Autor:
Seok Rye Choi, Hank F. Kung, Shengyu Shi, Haiyan Hong, Lin Zhu, Lifang Zhang, Zehui Wu, Aili Zhang
Publikováno v:
Nuclear Medicine and Biology. :17-24
Introduction [68Ga]Ga-EDTA ([68Ga]Ga-ethylenediaminetetraacetic acid) was previously reported as a renal imaging agent for measuring GFR (glomerular filtration rate). In an effort to provide new agents with better in vivo characteristics for renal im
Autor:
Hao Xiao, Karl Ploessl, Zhihao Zha, Lin Zhu, Ruiyue Zhao, Hank F. Kung, Seok Rye Choi, David Alexoff
Publikováno v:
ACS Med Chem Lett
[Image: see text] [(18)F]AV-45 (florbetapir f18, Amyvid) is an FDA-approved PET imaging agent targeting Aβ plaques in the brain for diagnosis of Alzheimer’s disease (AD). Its metabolites led to a high background in the brain and large bone uptake
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0260b88b3770e22ad99887ce1941f867
https://europepmc.org/articles/PMC8274066/
https://europepmc.org/articles/PMC8274066/
Autor:
Zhihao, Zha, Seok Rye, Choi, Karl, Ploessl, David, Alexoff, Ruiyue, Zhao, Lin, Zhu, Hank F, Kung
Publikováno v:
Bioconjugate chemistry. 32(5)
Prostate-specific membrane antigen (PSMA)-targeted radioligands have played an increasing role in the diagnosis of prostate cancer. [